Biotricity (OTCMKTS:BTCY) vs. MDxHealth (NASDAQ:MDXH) Head-To-Head Survey

MDxHealth (NASDAQ:MDXH) and Biotricity (OTCMKTS:BTCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Analyst Ratings

This is a summary of recent recommendations for MDxHealth and Biotricity, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	0	4	0	2.60
Biotricity	0	0	0	0	0.00

MDxHealth currently has a consensus price target of $7.75, suggesting a potential upside of 137.00%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts clearly believe MDxHealth is more favorable than Biotricity.

Earnings & Valuation

This table compares MDxHealth and Biotricity”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$90.05 million	1.72	-$38.07 million	($0.64)	-5.11
Biotricity	$13.79 million	0.64	-$8.42 million	($0.17)	-1.87

Biotricity has lower revenue, but higher earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MDxHealth has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Insider & Institutional Ownership

3.9% of Biotricity shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MDxHealth and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-30.50%	-1,078.01%	-20.05%
Biotricity	-30.02%	N/A	-75.50%

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.